Seres Health appoints new President and CEO

Roger Pomerantz was previously Head of Licensing & Acquisitions at Merck & Co

Seres Health, a clinical-stage therapeutics company based in Cambridge, MA in the US has appointed Roger Pomerantz as President and Chief Executive.

Pomerantz has been Chairman of the company since last November.

Seres Health develops products to treat a host of disease conditions based on scientific findings related to the human microbiome.

Pomerantz was most recently Senior Vice President and Worldwide Head of Licensing & Acquisitions at Merck & Co, where he oversaw all licensing and acquisitions at Merck Research Laboratories. Prior to this he was Senior Vice President and Global Franchise Head of Infectious Diseases at Merck.

Before joining Merck, Pomerantz was Global Head of Infectious Diseases at Johnson & Johnson Pharmaceuticals, responsible for all anti-infective agents worldwide. He joined Johnson & Johnson in 2005 as President of Tibotec Pharmaceuticals.

You may also like

Research & Development

AstraZeneca and Seres investigate impact of the microbiome on cancer medication

A three-year collaboration will use Seres’ expertise on the microbiome to evaluate the potential for a combined therapy with standard pharmaceuticals
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Manufacturing

Anton Paar expands Litesizer DIA Series with new models

Introducing affordable and advanced solutions for particle analysis
Manufacturing

Triple your efficiency with the new DrySyn Vortex

Boost productivity with temperature-controlled parallel reactions
Manufacturing

Five critical design elements for Pelton wheel turbine flowmeters

Titan Enterprises outlines the factors for cost-effective and reliable low-flow measurement
Subscribe now